ライフサイエンスコーパス: obliterans

1 lung allograft recipients with bronchiolitis obliterans.

2 t of interstitial fibrosis and bronchiolitis obliterans.

3 opathic pneumonia syndrome and bronchiolitis obliterans.

4 nt might be an option to treat bronchiolitis obliterans.

5 the condition is often called bronchiolitis obliterans.

6 ome the challenge presented by bronchiolitis obliterans.

7 angiographically involved in thromboangiitis obliterans.

8 rcome in long-term survival is bronchiolitis obliterans.

9 t were reported to have severe bronchiolitis obliterans.

10 cute rejection; none developed bronchiolitis obliterans.

11 irway obstruction arising from bronchiolitis obliterans.

12 manifesting as scleroderma and bronchiolitis obliterans.

13 dysfunction characteristic of bronchiolitis obliterans.

14 ed pulmonary fibrosis (3%) and bronchiolitis obliterans (3%).

15 mmon causes of late death were bronchiolitis obliterans (35/61, 57%), infection (13/61, 21%), and pos

16 ival was 77% for patients with bronchiolitis obliterans, 37% for patients with IPS, and 36% for patie

17 s (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse panbronchiolit

18 d accuracy in diagnosing early bronchiolitis obliterans after lung transplantation.

19 ciated with the development of bronchiolitis obliterans after transplantation, we determined whether

20 y a role in the development of bronchiolitis obliterans after transplantation.

21 Asthma as well as bronchiolitis obliterans and chronic bronchitis are chronic lung disea

22 eatures distinguishing it from bronchiolitis obliterans and idiopathic pulmonary fibrosis.

23 stic fibrosis, post-transplant bronchiolitis obliterans and more recently chronic obstructive pulmona

24 ociations between diacetyl and bronchiolitis obliterans and other severe respiratory diseases observe

25 uent disease, earlier onset of bronchiolitis obliterans and shorter survival.

26 ht be helpful to better manage bronchiolitis obliterans and to detect and treat it earlier.

27 however, including infections, bronchiolitis obliterans, and complications of immunosuppression remai

28 atients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung transplant.

29 c pneumonia syndrome (IPS) and bronchiolitis obliterans are now recognized as part of a spectrum of p

30 multiorgan system injury with bronchiolitis obliterans associated with a robust GC reaction, but not

31 of patients with fibrosis and bronchiolitis obliterans, at each successive scheduled surveillance ti

32 and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectively, for which

33 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, we used an esta

34 Bronchiolitis obliterans (BO) is a detrimental late pulmonary complica

35 Bronchiolitis obliterans (BO) is the pathologic manifestation of chron

36 of lung transplantation, with bronchiolitis obliterans (BO) representing the predominant pathologica

37 The pathogenesis of bronchiolitis obliterans (BO), a common and devastating obliterative d

38 graft survival, occurrence of bronchiolitis obliterans (BO), and episodes of rejection.

39 chanism driving posttransplant bronchiolitis obliterans (BO), and its clinical correlate bronchioliti

40 em disease model that includes bronchiolitis obliterans (BO), dependent upon GC B cells, Tfhs, and co

41 n a multiorgan system model of bronchiolitis obliterans (BO), driven by germinal center reactions and

42 y obliteration, which leads to bronchiolitis obliterans (BO), which is pathognomonic for cGVHD of the

43 ymphocytic bronchitis (LB) and bronchiolitis obliterans (BO).

44 ant murine model of cGVHD with bronchiolitis obliterans (BO).

45 system cGVHD model that induces bronchiolar obliterans (BO).

46 viremia increases the risk of bronchiolitis obliterans (BOS) or death and retransplantation in the f

47 traluminal fibrotic lesions of bronchiolitis obliterans by day 28.

48 they probably had occupational bronchiolitis obliterans caused by the inhalation of volatile butter-f

49 on and with the development of bronchiolitis obliterans could not be confirmed in human lung allograf

50 Therefore, earlier bronchiolitis obliterans detection and more timely implementation of E

51 Bronchiolitis obliterans developed in 29% of patients with a BALT-posi

52 hat results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

53 tion course was complicated by bronchiolitis obliterans from chronic rejection and by recent pulmonar

54 se; in contrast, patients with bronchiolitis obliterans from Stevens-Johnson syndrome often have prog

55 Patients with postinfectious bronchiolitis obliterans generally have chronic, nonprogressive diseas

56 ith histopathologically proved bronchiolitis obliterans (group A) and 21 with normal biopsy findings

57 Experimental models of IPS and bronchiolitis obliterans have proven useful to test strategies designe

58 ied to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

59 The diagnosis of bronchiolitis obliterans in children can be made with confidence based

60 sis, treatment, and outcome of bronchiolitis obliterans in the nontransplant, pediatric population.

61 cidence of acute rejection and bronchiolitis obliterans in younger versus older children may reveal i

62 WT APC normalized bronchiolitis obliterans-induced pulmonary dysfunction.

63 Thromboangiitis obliterans is a nonatherosclerotic segmental inflammator

64 ifferent cGVHD model, in which bronchiolitis obliterans is a prominent manifestation, F4/80+ macropha

65 Bronchiolitis obliterans is a rare form of chronic obstructive lung di

66 st disease (GVHD) and IPS, and bronchiolitis obliterans is pathognomonic of chronic GVHD.

67 udying rare diseases such as thromboangiitis obliterans is that there are no significant research dol

68 Bronchiolitis obliterans is the leading cause of chronic graft failure

69 al Intelligence, Air Trapping, Bronchiolitis Obliterans, Lung Transplant Supplemental material is ava

70 ary vascular disease (n = 44), bronchiolitis obliterans (n = 21), pulmonary alveolar proteinosis (n =

71 me (n=4), hemosiderosis (n=1), bronchiolitis obliterans (n=1), sarcoidosis (n=1), and bronchiectasis

72 monary vascular disease (n=6), bronchiolitis obliterans (n=2), bronchopulmonary dysplasia (n=1), graf

73 neumonia syndrome (IPS, n=19), bronchiolitis obliterans (n=22), and other uncommon syndromes (n=5).

74 Bronchiolitis obliterans organizing pneumonia (BOOP) and acute respira

75 The peak prevalence of bronchiolitis obliterans organizing pneumonia (BOOP) and interstitial

76 Bronchiolitis obliterans organizing pneumonia (BOOP) has been reported

77 se alveolar damage (DAD) in 2, bronchiolitis obliterans organizing pneumonia (BOOP) in 1, and usual i

78 Bronchiolitis obliterans organizing pneumonia (BOOP) is a clinical syn

79 Bronchiolitis obliterans organizing pneumonia (BOOP) is a term that wa

80 neumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others.

81 hin air spaces consistent with bronchiolitis obliterans organizing pneumonia (BOOP).

82 obliterans syndrome (BOS), and bronchiolitis obliterans organizing pneumonia (BOOP).

83 ory distress syndrome (n = 2), bronchiolitis obliterans organizing pneumonia (n = 2), pulmonary embol

84 is, oral herpetic lesions, and bronchiolitis obliterans organizing pneumonia after 2 episodes of bact

85 Bronchiolitis obliterans organizing pneumonia and erythema nodosum are

86 e case of a lady who developed bronchiolitis obliterans organizing pneumonia and erythema nodosum sim

87 ganizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulmonary Langerha

88 ic interstitial pneumonitis, bronchoalveolar obliterans organizing pneumonia, focal fibrosis, pulmona

89 pneumonia, and the seventh had bronchiolitis obliterans organizing pneumonia.

90 ulates pulmonary fibrosis from bronchiolitis obliterans, recipients of Tet2-deleted donor T cells did

91 The pathomechanism of bronchiolitis obliterans remains unclear and it remains a fatal compli

92 within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.6 [0.6-17.1] p

93 T studies in six patients with bronchiolitis obliterans syndrome (age range, 2 months to 5 1/2 years)

94 omegalovirus increases risk of bronchiolitis obliterans syndrome (aHR, 2.88; 95% CI, 1.50-5.55; P = 0

95 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic

96 are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic

97 Bronchiolitis obliterans syndrome (BOS) after lung transplantation (LT

98 Bronchiolitis obliterans syndrome (BOS) after lung transplantation is

99 orphisms on the development of bronchiolitis obliterans syndrome (BOS) after lung transplantation.

100 ng log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft survival were compar

101 nally recognized definition of bronchiolitis obliterans syndrome (BOS) and longer follow up of heart-

102 raft dysfunction manifested as bronchiolitis obliterans syndrome (BOS) and worse posttransplant survi

103 Freedom from bronchiolitis obliterans syndrome (BOS) at three years was similar in

104 cur frequently post-HSCT, with bronchiolitis obliterans syndrome (BOS) being the most common noninfec

105 Bronchiolitis obliterans syndrome (BOS) cases had lower scores for int

106 Development of bronchiolitis obliterans syndrome (BOS) following lung transplantation

107 therapy for the management of bronchiolitis obliterans syndrome (BOS) has been sparsely reported in

108 an system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine model, we hypothes

109 n on survival and the onset of bronchiolitis obliterans syndrome (BOS) in consecutive lung transplant

110 associated with development of bronchiolitis obliterans syndrome (BOS) in human lung allografts.

111 ansplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients, primarily a

112 ansplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients, primarily a

113 The term bronchiolitis obliterans syndrome (BOS) is a clinical surrogate for th

114 Bronchiolitis obliterans syndrome (BOS) is a condition of progressive

115 Background: Bronchiolitis obliterans syndrome (BOS) is a late-onset noninfectious

116 Bronchiolitis obliterans syndrome (BOS) is a major impediment to lung

117 Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding p

118 ograft rejection manifested as bronchiolitis obliterans syndrome (BOS) is the leading cause of late d

119 Bronchiolitis obliterans syndrome (BOS) is the major limitation to sur

120 Bronchiolitis obliterans syndrome (BOS) is the major limitation to sur

121 Bronchiolitis obliterans syndrome (BOS) is the major obstacle to long-

122 Bronchiolitis obliterans syndrome (BOS) is the most common cause of mo

123 Bronchiolitis obliterans syndrome (BOS) is the primary limiting factor

124 function (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndr

125 lant recipients suffering from bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndr

126 elopment of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major limiting factors

127 Bronchiolitis obliterans syndrome (BOS) remains the leading obstacle t

128 Bronchiolitis obliterans syndrome (BOS) remains the main cause of graf

129 of the allograft airway during bronchiolitis obliterans syndrome (BOS) that occurs after lung transpl

130 Bronchiolitis obliterans syndrome (BOS), a condition of irreversible s

131 ung transplant recipients with bronchiolitis obliterans syndrome (BOS), a condition previously regard

132 nfectious complications and by bronchiolitis obliterans syndrome (BOS), a form of chronic rejection l

133 Bronchiolitis obliterans syndrome (BOS), a process of fibro-obliterati

134 rvival and a high incidence of bronchiolitis obliterans syndrome (BOS), an inflammation of the small

135 thic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolitis obliterans

136 ic rejection that manifests as bronchiolitis obliterans syndrome (BOS), but no biomarker can currentl

137 CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect of pseudomonas

138 ransplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the dominant chall

139 ve airflow obstruction, termed bronchiolitis obliterans syndrome (BOS), is the major cause of poor ou

140 raft rejection, represented by bronchiolitis obliterans syndrome (BOS), is the single most important

141 orders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and graft loss for

142 Bronchiolitis obliterans syndrome (BOS), pathognomonic for chronic gra

143 unction (CLAD), and especially bronchiolitis obliterans syndrome (BOS), remain dominant causes of mor

144 Bronchiolitis obliterans syndrome (BOS), the clinical correlate of chr

145 Bronchiolitis obliterans syndrome (BOS), the major cause of death on l

146 literative lesion found during bronchiolitis obliterans syndrome (BOS), we hypothesized that the type

147 phy morphology, mortality, and bronchiolitis obliterans syndrome (BOS)-free survival were analyzed up

148 of chronic rejection, known as bronchiolitis obliterans syndrome (BOS).

149 ury would increase the risk of bronchiolitis obliterans syndrome (BOS).

150 an established risk factor for bronchiolitis obliterans syndrome (BOS).

151 ften due to the development of bronchiolitis obliterans syndrome (BOS).

152 limited by the development of bronchiolitis obliterans syndrome (BOS).

153 fection) (NORMAL POST) or with bronchiolitis obliterans syndrome (BOS).

154 ecline in lung function termed bronchiolitis obliterans syndrome (BOS).

155 r lung transplantation (LT) is bronchiolitis obliterans syndrome (BOS).

156 ortant role in the etiology of bronchiolitis obliterans syndrome (BOS).

157 elated with the development of bronchiolitis obliterans syndrome (BOS).

158 fluid samples from LTxRs with bronchiolitis obliterans syndrome (BOS).

159 factor for the development of bronchiolitis obliterans syndrome (BOS).

160 L-CsA-i) for the prevention of bronchiolitis obliterans syndrome (BOS).

161 mary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

162 O), and its clinical correlate bronchiolitis obliterans syndrome (BOS).

163 y contribute to development of bronchiolitis obliterans syndrome (BOS).

164 ronic allograft failure termed bronchiolitis obliterans syndrome (BOS).

165 ol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Everolimus group

166 outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of acute rejection.

167 in obliterative bronchiolitis/bronchiolitis obliterans syndrome (OB/BOS), which severely limits surv

168 09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observed in the Celsi

169 nor a subsequent diagnosis of bronchiolitis obliterans syndrome (P=0.70).

170 rejection of lung allografts (bronchiolitis obliterans syndrome [BOS]) and proinflammatory cytokines

171 r causes (currently defined as bronchiolitis obliterans syndrome [BOS]) is considered to reflect the

172 ts may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictive lung functio

173 iagnosis of chronic rejection (bronchiolitis obliterans syndrome [BOS]) was made in 191 patients (42.

174 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS-restrictive a

175 nfants and young children with bronchiolitis obliterans syndrome after lung transplantation are more

176 f multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismatch model of sc

177 investigate the development of bronchiolitis obliterans syndrome and graft loss after LTX in relation

178 graft rejection in the form of bronchiolitis obliterans syndrome and its histopathologic correlate, o

179 se current literature suggests bronchiolitis obliterans syndrome and restrictive allograft syndrome a

180 ructive and restrictive forms: bronchiolitis obliterans syndrome and restrictive allograft syndrome.

181 s 2 major clinical phenotypes: bronchiolitis obliterans syndrome and restrictive allograft syndrome.

182 urrent diagnostic criteria for bronchiolitis obliterans syndrome and reviews the epidemiology, pathog

183 plant recipients who developed bronchiolitis obliterans syndrome and were compared to stable controls

184 Emphysema, female gender, and bronchiolitis obliterans syndrome are risk factors for severe HGG.

185 ted that the increased risk of bronchiolitis obliterans syndrome associated with primary graft dysfun

186 ints were overall survival and bronchiolitis obliterans syndrome at 2 years.

187 predisposed to development of bronchiolitis obliterans syndrome but particularly to restrictive allo

188 rvival and an earlier onset of bronchiolitis obliterans syndrome compared with patients in the transp

189 tial new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomized placebo co

190 This resembles bronchiolitis obliterans syndrome developed following human lung trans

191 r clinical variables including bronchiolitis obliterans syndrome did not change this relationship.

192 sease affects the lung tissue, bronchiolitis obliterans syndrome ensues.

193 wever, toward reduced onset of bronchiolitis obliterans syndrome grade 2 or 3 was observed in TLR4 he

194 multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV1% predicted (

195 Patients with bronchiolitis obliterans syndrome had a higher risk of severe HGG than

196 Bronchiolitis obliterans syndrome has been associated with increased m

197 roblasts in the development of bronchiolitis obliterans syndrome has not been evaluated.

198 ansplantation, and potentially bronchiolitis obliterans syndrome in lung transplant recipients, with

199 de therapy in the treatment of bronchiolitis obliterans syndrome in lung transplant recipients.

200 gress of medical management of bronchiolitis obliterans syndrome include difficulties and delays in d

201 ated with an increased risk of bronchiolitis obliterans syndrome independent of acute rejection, lymp

202 Bronchiolitis obliterans syndrome is a fibrotic occlusion of distal ai

203 Bronchiolitis obliterans syndrome is a major problem for medium-to-lon

204 Bronchiolitis obliterans syndrome is caused by a fibroproliferative pr

205 Bronchiolitis obliterans syndrome is characterized by fibrotic obliter

206 Bronchiolitis obliterans syndrome is the leading cause of chronic lung

207 ed into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), early CLAD (BOS 0p

208 Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of HSCT recipien

209 graft dysfunction manifests as bronchiolitis obliterans syndrome or the recently described restrictiv

210 factor for the development of bronchiolitis obliterans syndrome or worse overall survival.

211 nted lungs from four end-stage bronchiolitis obliterans syndrome patients was analyzed using laser-ca

212 portantly, the 2014 NIH-CC for bronchiolitis obliterans syndrome perform poorly in children.

213 Bronchiolitis obliterans syndrome remains the leading cause of morbidi

214 spiratory viral infection is a bronchiolitis obliterans syndrome risk factor and virus-dependent inju

215 he remaining four patients had bronchiolitis obliterans syndrome scores of 0 compared with 5 of 13 co

216 Bronchiolitis Obliterans Syndrome seriously reduces long-term survival

217 ignificantly increased risk of bronchiolitis obliterans syndrome stage 1 (grade 1: relative risk [RR]

218 n, lymphocytic bronchitis, and bronchiolitis obliterans syndrome stage 1, using univariable and multi

219 Freedom from bronchiolitis obliterans syndrome was lower, and mortality was higher

220 n of bronchial dilatation with bronchiolitis obliterans syndrome was significant (P = .02).

221 atients with clinically proved bronchiolitis obliterans syndrome were mosaic perfusion in five (83%)

222 Small airway fibrosis (bronchiolitis obliterans syndrome) is the primary obstacle to long-ter

223 onic lung allograft rejection (bronchiolitis obliterans syndrome) remains to be elucidated.

224 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin gr

225 Bronchiolitis obliterans syndrome, a common form of chronic lung allog

226 al RNA (HCV RNA), freedom from bronchiolitis obliterans syndrome, acute rejection, and survival.

227 factor for the development of bronchiolitis obliterans syndrome, an important cause of late mortalit

228 , renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

229 months, bacterial infections, bronchiolitis obliterans syndrome, and survival.

230 five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatment improved fo

231 limited by chronic rejection (bronchiolitis obliterans syndrome, BOS).

232 remained STA, and 37 had CLAD (bronchiolitis obliterans syndrome, BOS, [n = 32] or restrictive allogr

233 rophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled trial is awaited.

234 ion is a major risk factor for bronchiolitis obliterans syndrome, but noninvasive biomarkers have not

235 e altered airway epithelium of bronchiolitis obliterans syndrome, including substantial emergence of

236 graft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term su

237 Unlike bronchiolitis obliterans syndrome, it is not universally acknowledged

238 ses and in the pathogenesis of bronchiolitis obliterans syndrome, the predominant manifestation of ch

239 licated in the pathogenesis of bronchiolitis obliterans syndrome, which is considered to represent ch

240 g lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clinical and histo

241 ality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

242 ate the in vivo development of bronchiolitis obliterans syndrome-like lesions and reveal its sensitiv

243 g allograft rejection known as bronchiolitis obliterans syndrome.

244 tudy subjects remain free from bronchiolitis obliterans syndrome.

245 f primary graft dysfunction on bronchiolitis obliterans syndrome.

246 factor for the development of bronchiolitis obliterans syndrome.

247 served in the overall onset of bronchiolitis obliterans syndrome.

248 idence of post-lung transplant bronchiolitis obliterans syndrome.

249 limited by the development of bronchiolitis obliterans syndrome.

250 lung function in patients with bronchiolitis obliterans syndrome.

251 factor for the development of bronchiolitis obliterans syndrome.

252 n linked to the development of bronchiolitis obliterans syndrome.

253 te rejection (AR) or developed bronchiolitis obliterans syndrome.

254 iopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

255 Four patients developed bronchiolitis obliterans syndrome.

256 n increased risk of developing bronchiolitis obliterans syndrome.

257 l to mesenchymal transition in bronchiolitis obliterans syndrome.

258 lung transplantation (LTX) is bronchiolitis obliterans syndrome.

259 patients prior to diagnosis of bronchiolitis obliterans syndrome.

260 montelukast should be used for bronchiolitis obliterans syndrome; and the addition of newer treatment

261 acute cellular rejection, and bronchiolitis obliterans syndrome; however, the significance of circul

262 injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' cascade present sig

263 rease the chance of developing bronchiolitis obliterans; therefore, many centers perform surveillance

264 overall rate of occurrence of bronchiolitis obliterans was 46% (80/175) and the overall incidence of

265 onic illness in which meningeal endarteritis obliterans was consistently observed.

266 factors for the development of bronchiolitis obliterans were age older than 3 years, more than two ep

267 associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing virus, LCMV.

268 onsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on antibody and germ

269 he major late complication was bronchiolitis obliterans, which occurred in 27% of patients and played

270 Bronchiolitis obliterans with organizing pneumonia (BOOP) was the most

271 athy and pulmonary findings of bronchiolitis obliterans with organizing pneumonia (BOOP).